Citation: | ZHAO Qi, ZHU Pinghui, MA Li, LYU Taihong, CHEN Yuru. Relationship between plasma apolipoprotein A1 level and mild cognitive impairment in middle-aged and elderly patients with type 2 diabetes mellitus[J]. Chinese Journal of General Practice, 2025, 23(6): 912-915. doi: 10.16766/j.cnki.issn.1674-4152.004030 |
[1] |
田金洲, 解恒革, 王鲁宁, 等. 中国阿尔茨海默病痴呆诊疗指南(2020年版)[J]. 中华老年医学杂志, 2021, 40(3): 269-283. doi: 10.3760/cma.j.issn.0254-9026.2021.03.001
TIAN J Z, XIE H G, WANG L N, et al. Chinese guideline for the diagnosis and treatment of Alzheimer's disease dementia (2020)[J]. Chinese Journal of Geriatrics, 2021, 40(3): 269-283. doi: 10.3760/cma.j.issn.0254-9026.2021.03.001
|
[2] |
JIA L, DU Y, CHU L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study[J]. Lancet Public Health, 2020, 5(12): e661-e671. doi: 10.1016/S2468-2667(20)30185-7
|
[3] |
王琼, 王国平. 阿尔茨海默病的诊断与治疗[J]. 中华全科医学, 2019, 17(8): 1255-1256. http://www.zhqkyx.net/article/id/18f73bba-8d0a-4fc0-8880-f792d4b6bd77
WANG Q, WANG G P. Diagnosis and treatment of Alzheimer's disease[J]. Chinese Journal of General Practice, 2019, 17(8): 1255-1256. http://www.zhqkyx.net/article/id/18f73bba-8d0a-4fc0-8880-f792d4b6bd77
|
[4] |
ANDERSON N D. State of the science on mild cognitive impairment (MCI)[J]. CNS Spectr, 2019, 24(1): 78-87. doi: 10.1017/S1092852918001347
|
[5] |
JONGSIRIYANYONG S, LIMPAWATTANA P. Mild cognitive impairment in clinical practice: a review article[J]. Am J Alzheimers Dis Other Demen, 2018, 33(8): 500-507. doi: 10.1177/1533317518791401
|
[6] |
QARNI T, SALARDINI A. A multifactor approach to mild cognitive impairment[J]. Semin Neurol, 2019, 39(2): 179-187. doi: 10.1055/s-0039-1678585
|
[7] |
ALI M K, PEARSON-STUTTARD J, SELVIN E, et al. Interpreting global trends in type 2 diabetes complications and mortality[J]. Diabetologial, 2022, 65(1): 3-13. doi: 10.1007/s00125-021-05585-2
|
[8] |
BIESSELS G J, NOBILI F, TEUNISSEN C E, et al. Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective[J]. Lancet Neurol, 2020, 19(8): 699-710. doi: 10.1016/S1474-4422(20)30139-3
|
[9] |
XUE M, XU W, OU Y N, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies[J]. Ageing Res Rev, 2019, 55: 100944. DOI: 10.1016/j.arr.2019.100944.
|
[10] |
POWER M C, RAWLINGS A, SHARRETT A R, et al. Association of midlife lipids with 20-year cognitive change: a cohort study[J]. Alzheimers Dement, 2018, 14(2): 167-177. doi: 10.1016/j.jalz.2017.07.757
|
[11] |
MARTENS Y A, ZHAO N, LIU C C, et al. ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias[J]. Neuron, 2022, 110(8): 1304-1317. doi: 10.1016/j.neuron.2022.03.004
|
[12] |
中华医学会糖尿病学分会, 朱大龙. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4): 311-398. doi: 10.3760/cma.j.cn311282-20210304-00142
Chinese Diabetes Society, ZHU D L. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. Chinese Journal of Endocrinology and Metabolism, 2021, 37(4): 311-398. doi: 10.3760/cma.j.cn311282-20210304-00142
|
[13] |
CORREA Y, RAVEL M, IMBERT M, et al. Lipid exchange of apolipoprotein AI amyloidogenic variants in reconstituted high-density lipoprotein with artificial membranes[J]. Protein Sci, 2024, 33(5): e4987. DOI: 10.1002/pro.4987.
|
[14] |
ENDRES K. Apolipoprotein A1, the neglected relative of Apolipoprotein E and its potential role in Alzheimer's disease[J]. Neural Regen Res, 2021, 16(11): 2141-2148. doi: 10.4103/1673-5374.310669
|
[15] |
PILLAI J A, BENA J, BEKRIS L, et al. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease[J]. Alzheimers Res Ther, 2023, 15(1): 54. DOI: 10.1186/s13195-023-01203-y.
|
[16] |
DENG X, SAFFARI S E, NG S Y E, et al. Blood lipid biomarkers in early Parkinson's disease and Parkinson's disease with mild cognitive impairment[J]. J Parkinsons Dis, 2022, 12(6): 1937-1943. doi: 10.3233/JPD-213135
|
[17] |
PILLAI J A, MAXWELL S, BENA J, et al. Key inflammatory pathway activations in the MCI stage of Alzheimer's disease[J]. Ann Clin Transl Neurol, 2019, 6(7): 1248-1262. doi: 10.1002/acn3.50827
|
[18] |
TONG J H, GONG S Q, ZHANG Y S, et al. Association of circulating apolipoprotein AI levels in patients with Alzheimer's disease: a systematic review and meta-analysis[J]. Front Aging Neurosci, 2022, 14: 899175. DOI: 10.3389/fnagi.2022.899175.
|
[19] |
GUO Y, LI P, MA X, et al. Association of circulating cholesterol level with cognitive function and mild cognitive impairment in the elderly: a community-based population study[J]. Curr Alzheimer Res, 2020, 17(6): 556-565. doi: 10.2174/1567205017666200810165758
|
[20] |
NORDESTGARRD L T, CHRISTOFFERSEN M, AFZAL S, et al. Triglycerides as a shared risk factor between dementia and atherosclerotic cardiovascular disease: a study of 125 727 individuals[J]. Clin Chem, 2021, 67(1): 245-255. doi: 10.1093/clinchem/hvaa269
|